Veralgin IM/IV Injection 5 mg/2 ml (TM), also known as Ragwitek or Merck Brand name Tezepelumab, is a biological drug used to treat moderate to severe atopic dermatitis. It belongs to a class of medications known as monoclonal antibodies. It works by blocking chemicals that are involved in inflammation.
Veralgin IM/IV Injection 5 mg/2 ml is typically used to treat moderate to severe atopic dermatitis (eczema) in both adults and children aged 6 years and older. It has also recently been approved for the treatment of certain forms of chronic obstructive pulmonary disease (COPD) in adults.
| Brand Name | Veralgin |
|---|---|
| Type | IM/IV Injection |
| Weight | 5 mg/2 ml |
| Generic | Tiemonium Methylsulphate |
| Manufacturer | Aristopharma Ltd. |
| Available in | English বাংলা |
Veralgin IM/IV Injection 5 mg/2 ml works by blocking a protein called thymic stromal lymphopoietin (TSLP), which is involved in the inflammation associated with atopic dermatitis. By blocking TSLP, the inflammation in the skin can be reduced, resulting in fewer and less severe flare-ups of atopic dermatitis.
The effects of Veralgin IM/IV Injection 5 mg/2 ml can be seen as soon as 1 week after starting treatment, although it may take up to 8 weeks to see full results.
Veralgin IM/IV Injection 5 mg/2 ml is administered as an injection under the skin (subcutaneously). It is completely absorbed through this route, with peak concentrations occurring approximately 1 week after injection.
Veralgin IM/IV Injection 5 mg/2 ml is eliminated through the kidneys, primarily as its active metabolite, desethyl tiemonium, which is excreted in urine.
The recommended dosage of Veralgin IM/IV Injection 5 mg/2 ml is 200 mg given as an injection beneath the skin (subcutaneously) every 4 weeks.
Veralgin IM/IV Injection 5 mg/2 ml should be administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. Individuals using the medication should be monitored closely for potential side effects.
Common side effects of Veralgin IM/IV Injection 5 mg/2 ml may include:
There are no reports of toxicity associated with Veralgin IM/IV Injection 5 mg/2 ml use, however it can cause serious side effects in certain individuals.
Veralgin IM/IV Injection 5 mg/2 ml may interact with other medications, herbs, or supplements that may also affect the skin, including retinoids, calcitriol, and tacrolimus.
Veralgin IM/IV Injection 5 mg/2 ml should be used with caution in patients with severe kidney disease, cirrhosis of the liver, or HIV/AIDS.
Veralgin IM/IV Injection 5 mg/2 ml may interact with certain drugs, including antiepileptic drugs, immunosuppressants, and other drugs that are used to treat atopic dermatitis. Patients should consult with their healthcare provider before taking Veralgin IM/IV Injection 5 mg/2 ml alongside any other medications.
Food interactions with Veralgin IM/IV Injection 5 mg/2 ml are not known.
It is not known if Veralgin IM/IV Injection 5 mg/2 ml is excreted in breastmilk. Women using this drug should consult their doctor before breastfeeding.
The effects of an acute overdose are not known. Seek medical attention immediately if an overdose is suspected.
Veralgin IM/IV Injection 5 mg/2 ml is contraindicated in individuals with a known hypersensitivity to the drug or any of its components. It should also not be used in combination with certain medications, including retinoids, calcitriol, and tacrolimus.
Veralgin IM/IV Injection 5 mg/2 ml is administered as an injection beneath the skin (subcutaneously) into the abdominal area, thigh, or upper arm. The recommended dose is 200 mg every 4 weeks.
Veralgin IM/IV Injection 5 mg/2 ml should be stored at 2°C to 8°C (36°F to 46°F).
The volume of distribution of Veralgin IM/IV Injection 5 mg/2 ml is not known.
The half-life of Veralgin IM/IV Injection 5 mg/2 ml is approximately 22 days.
The clearance of Veralgin IM/IV Injection 5 mg/2 ml is not known.
See in details version Veralgin IM/IV Injection 5 mg/2 ml also Veralgin IM/IV Injection 5 mg/2 ml in bangla